CF
NAGE

Corebridge Financial’s Niagen Bioscience NAGE Stock Holding History

Corebridge Financial’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,259
Closed -$167K – 2991
2025
Q1 		$167K Sell
24,259
-359
-1% -$2.26K ﹤0.01% 2174
2024
Q4 		$131K Sell
24,618
-1,560
-6% -$8.54K ﹤0.01% 2423
2024
Q3 		$95.5K Sell
26,178
-161
-0.6% -$507 ﹤0.01% 2640
2024
Q2 		$72.2K Buy
+26,339
New +$88.1K ﹤0.01% 2770

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Corebridge Financial's NAGE Position: Q2 2025 in Review

Corebridge Financial sold out of Niagen Bioscience (NAGE) in Q2 2025, closing a stake of 24,259 shares — an estimated $167K sold.

Corebridge Financial first reported a position in NAGE in Q2 2024 and held it in 4 quarters. The position peaked at $167K in Q1 2025. 155 funds tracked by Wall St. Rank hold NAGE as of Q2 2025.

  • Corebridge Financial reported no remaining Niagen Bioscience position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 24,259 Niagen Bioscience shares in Q2 2025, an estimated $167K.
  • Corebridge Financial first reported a position in Niagen Bioscience in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Niagen Bioscience position peaked at $167K in Q1 2025.
  • 155 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.